ResultsIQ

ResultsIQ › Latest results › Nureca Limited

Nureca Limited Q4 FY25 results deck summary

NSE: NURECA · BSE: 543264

Results deck of 5 May 2025, summarised by AI from the filing.

Entered a new agreement with Swiggy, a quick commerce player, to ensure faster product availability and expand market reach.

Key takeaways

  1. Swiggy agreement Entered a new agreement with Swiggy, a quick commerce player, to ensure faster product availability and expand market reach.
  2. FDA registration Nureca Technologies completed annual registration for its 510K exempt products with the US FDA for the Mohali, Punjab production facility.

Original filing on BSE

Nureca Limited Q1 FY27 results

As filed: Revenue ₹40.3 cr (+19% year on year), EBITDA ₹3.4 cr, PAT ₹3.1 cr (+207% year on year), EBITDA margin 8.5% (+1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹35.4 cr (+11% year on year), EBITDA −₹5.8 cr (−300% year on year), PAT −₹6.1 cr (−300% year on year), EBITDA margin -16.3% (−1,000 bps). Score 20 of 100, Below trend. Revenue growth was below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 11% from last quarter. Share price after the results: −14.6% in 27 days (Nifty 500: +2.0%).
  • Q3 FY26: Revenue ₹39.6 cr (+52% year on year), EBITDA ₹3.3 cr, PAT ₹3.7 cr, EBITDA margin 8.2% (+1,000 bps). Score 76 of 100, Above trend. Revenue growth was above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 47% of PBT. Revenue rose ₹13.6 cr on a year ago, more than the ₹4.0 cr it added the year before. Share price after the results: −8.5% in 30 days (Nifty 500: −0.1%).
  • H1 FY26: Revenue ₹72.0 cr, EBITDA ₹2.0 cr, PAT ₹4.0 cr, EBITDA margin 2.8%. Not scored. No result for the same half-year last year. Share price after the results: +12.3% in 29 days (Nifty 500: +1.2%).
  • Q1 FY26: Revenue ₹34.0 cr (+70% year on year), EBITDA −₹1.0 cr, PAT ₹1.0 cr (−50% year on year), EBITDA margin -2.9% (+706 bps). Score 61 of 100, In line with trend. Revenue growth was well above the company's own trend. EBITDA margin rose 706 bps year on year. Other income 300% of PBT. Tax rate 0%. Consolidated profit -50% but standalone +0%. Profit fell 50% from last quarter. Share price after the results: −18.4% in 30 days (Nifty 500: −3.3%).
  • Q4 FY25: Revenue ₹32.0 cr (+88% year on year), EBITDA ₹2.0 cr, PAT ₹2.0 cr, EBITDA margin 6.3% (+1,000 bps). Score 93 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 100% of PBT. Tax rate 0%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +20.5% in 30 days (Nifty 500: +2.8%).
  • Q3 FY25: Revenue ₹26.0 cr (+18% year on year), EBITDA −₹3.0 cr, PAT −₹3.0 cr, EBITDA margin -11.5% (+664 bps). Score 15 of 100, Below trend. Revenue growth was well above the company's own trend. EBITDA margin rose 664 bps year on year. Revenue fell 16% from last quarter.
  • Q2 FY25: Revenue ₹31.0 cr (0% year on year), EBITDA −₹2.0 cr (−200% year on year), PAT ₹0.0 cr (−100% year on year), EBITDA margin -6.5% (−1,000 bps). Score 9 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 100% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Nureca Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.